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Inhalation Toxicology and Carcinogenicity
of 1,3-Butadiene in B6C3F1 Mice Following
65 Weeks of Exposure
by Ronald L. Melnick,* J. E. Huff,* Joseph H.
Roycroft,* Billy J. Chou,t and Rodney A. Millert
1,3-Butadiene, a large-production volume chemical used mainly in the manufacture ofsynthetic rubber,
was found to induce multiple-organ carcinogenicity in male and female B6C3F1 mice at exposure con-
centrations (625and 1250ppm)equivalenttoandbelowtheOSHAstandardof1000ppm. Sincethisstudywas
terminated after 60 weeks of exposure because of reduced survival due to fatal tumors, and because
dose-responserelationships for1,3-butadiene-induced neoplastic andnonneoplasticlesionswerenotclearly
established, a second long-term inhalation study of1,3-butadiene in B6C3F1 mice was conducted at lower
exposure concentrations, ranging from 6.25 to 625 ppm. Both the histopathological findings from animals
dyingthroughweek65andtheresultsofevaluationsofanimalsexposedfor40and65weeksarepresentedin
this report. Exposure to 1,3-butadiene caused a regenerative anemia at concentrations of 62.5 ppm and
higher. Testicularatrophywasinduced at625ppm, andovarianatrophywasobserved at20ppmandhigher.
Duringthefirst50weeksofthestudy, lymphocytic lymphomawasthemajorcauseofdeathofmiceexposed
to 625 ppm 1,3-butadiene. Neoplasms ofthe heart, forestomach, lung, Harderian gland, mammary gland,
ovary, andliverwerefrequentlyobservedin1,3-butadiene-exposedmicethatdiedbetweenweek40andweek
65 of the study. Studies in which exposure to 1,3-butadiene was stopped after limited periods were also
included to assess the relationship between exposure levels and duration of exposures on the outcome of
1,3-butadiene-inducedcarcinogenicity. Inthesestudies,lymphocyticlymphomaswereinducedinmalemice
exposed to 625 ppm 1,3-butadiene foronly 13 weeks. The incidence oflymphocytic lymphoma in male mice
exposed to 625 ppm 1,3-butadiene for 26 weeks was two times that in mice exposed to 625 ppm for 13 weeks.
However, when the exposure concentration was reduced by half to 312 ppm and the exposure duration
extendedto52weeks, theincidenceoflymphocyticlymphomawasreducedby90%.Thus, themultipleofthe
exposureconcentrationtimestheexposuredurationdidnotpredicttheincidenceoflymphocyticlymphoma
in mice. The early mortalities resulting from lymphocytic lymphomas in male mice exposed to 625 ppm
1,3-butadiene limited the expression of tumors at other sites. A clearer dose-response for 1,3-butadiene-
induced neoplasia should be apparent from experiments in mice exposed to lower concentrations of this
chemical for 2 years.
Introduction
1,3-Butadiene is a colorless, flammable, noncorrosive
gas (bp: -4.4 °C, Vp: 1900mmHg at20°C) used mainly
in the production ofsynthetic rubber and thermoplastic
resins (1). In production volume, 1,3-butadiene is one of
thetop25organicchemicals manufactured inthe United
States (2), with an annual production level of rubber-
grade 1,3-butadiene in the U.S. of approximately 2.5
billion pounds (3). This gas has also been identified in
automobile exhaust, cigarette smoke, and in inciner-
ation products of fossil fuels (4). 1,3-Butadiene was
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selectedforevaluationofitstoxicologicandcarcinogenic
potential because of its large production volume, its
potentialforhumanexposureinfacilitiesthatproduceor
process this chemical, and the lack oflong-term toxicol-
ogy and carcinogenicity data forthis compound (5). The
National Institute for Occupational Safety and Health
estimates that about 65,000 workers are potentially
exposed to 1,3-butadiene (6), andthe U.S. Environmen-
tal Protection Agency estimates that between 5300 and
8200 workers are exposed to 1,3-butadiene in facilities
that either produce the monomer or process the mono-
mer into polymers (7). Recent surveys conducted by
NIOSH at monomer and polymer manufacturing plants
indicate that most occupational exposures to 1,3-bu-
tadiene are less than 20 ppm; however, excursions in
certain jobs were as high as 374 ppm (8).
1,3-Butadiene haslongbeenconsidered tohave alow,MELNICK ET AL.
noncumulative toxicity in animals and humans. The
LC50 for 1,3-butadiene was reported to be 270,000
mg/m3 (122,000 ppm) in mice exposed for 2 hr and
285,000mg/m3(129,000ppm)inratsexposedfor4hr(9).
Carpenter et al. (10) exposed rats, guineapigs, rabbits,
and dogs to 0, 600, 2300, or 6700 ppm 1,3-butadiene 7.5
hr/day, 6 days/week, for 8 months. Slight growth re-
tardation and cloudy swelling in hepatocytes were ob-
served in the highest dose group; there were no appar-
ent treatment-related pathologic changes inthe adrenal
gland, heart, kidneys, lungs, skeletal muscle, pancreas,
spleen, testes, or ovares. Exposure ofhumans to 2000
ppm 1,3-butadiene or higher for 6 to 8 hr caused slight
irritation ofthe eyes (9).
The National Toxicology Program (NTP) studied the
long-termeffectsofinhalationexposureto1,3-butadiene
in mice (5,11). Groups of50 male and 50 female B6C3F1
mice were exposed 6 hr/day, 5 days/week to air con-
taining 0 (chamber control), 625, or 1250 ppm 1,3-bu-
tadiene. This study, intended to last for 103 weeks, was
ended after 60 to 61 weeks because of cancer-related
mortalityinboth sexesatbothexposureconcentrations.
There were early induction and increased incidences of
malignant lymphomas, hemangiosarcomas ofthe heart,
alveolar-bronchiolar neoplasms, and squamous cell neo-
plasms of the forestomach in males and females; and
acinarcell carcinomas ofthemammarygland, granulosa
cell neoplasms of the ovary, and hepatocellular neo-
plasms in females. The observation ofhigh incidences of
hemangiosarcomas of the heart was a particularly un-
usualfinding, sincethehistoricalrateforthisuncommon
endothelial cell tumor is about 0.04% in untreated
B6C3F1 mice and has rarely been induced in B6C3F1
mice in long-term studies (12,13). In male mice, dose-
responses for neoplasms of the heart, lung, and fore-
stomach were notclearlydemonstrated sincebothdoses
produced similarresponses, whereasinfemalemice, the
rate of malignant lymphomas was lower than that in
males, and the dose-responses for other neoplastic le-
sions were more clearly defined.
Nonneoplastic lesions associated with exposure of
B6C3F1 miceto 1,3-butadiene included epithelialhyper-
plasia ofthe forestomach, endothelial hyperplasia ofthe
heart, alveolar epithelial hyperplasia, hepatocellular
necrosis, testicular atrophy, ovarian atrophy, and nasal
cavity lesions (chronic inflammation, fibrosis, and os-
seous and cartilagenous metaplasia in the olfactory re-
gion) in high-dose males (5,11).
Stimulated by the unusual effects of 1,3-butadiene in
mice, the fact that the studies were terminated early,
the sometimes unclear dose-response relationships for
variouslesions, andtheimportance of1,3-butadiene asa
high-production volume chemical with potential human
exposure, additional toxicology/carcinogenicity studies
ofvarious durations, including a 2-year exposure, were
initiated to better characterize dose-response relation-
ships for 1,3-butadiene-induced nonneoplastic and neo-
plastic lesions in B6C3F1 mice. Data from the first 65
weeks(15months)ofthatstudy(earlydeathanimalsand
interim evaluations at 40 and 65 weeks) are presented.
Thedatafromthe2-yearexposures arenotyetavailable
and will be reported separately.
Materials and Methods
Chemical and Exposure System
Liquified 1,3-butadiene of 99+% purity, containing
trace amounts oft-butyl catechol, a peroxide inhibitor,
was obtained from Phillips Chemical Co. (Borger, TX).
Concentrations of the dimer, 4-vinyl-1-cyclohexene, in
the cylinder headspace were determined by gas chro-
matographic analysis. Cylinders were not retained for
use if the dimer content was greater than 150 ppm.
1,3-Butadiene gas was metered to the exposure cham-
bersviaadistributionsystemanddilutedinthefreshair
chamber inlets. Chamber concentrations of 1,3-bu-
tadiene were monitored continuously during the ex-
posure periods with a Hewlett-Packard 5840 gas chro-
matograph equipped with a flame ionization detector
(oven temperature: 120°C; GC column: 12" x 1/8" nickel
column packed with 1% SP-1000 on 60/80 Carbopack B;
carrier gas: nitrogen, 20 mL/min). The daily mean con-
centrations of 1,3-butadiene, distributed uniformly in
the chambers, were within 2% of the target concen-
trations.
Animal Maintenance
Five-week-old male and female B6C3F1 mice, ob-
tained from Frederick Cancer Research Facility (Fred-
erick, MD), were quarantined and acclimatized for 10
days prior to the start of the study. Stainless steel
Hazelton2000chambers(2.3m3)wereused, andanimals
were exposed in individual wire mesh cage units, each
havingafloorareaof106cm2. Thechamberenvironment
was maintained at 75 + 3°F and 55 ± 15% relative
humidity, with a chamber air flow of 15 air changes/hr.
Fresh, softened tap water and NIH-07 diet were avail-
able ad libitum, except when the feed was removed
during the exposure periods and overnight prior to the
40- and 65-week necropsies.
Treatment Groups
Groups of 70 male and 70 female B6C3F1 mice were
exposed6hr/day, 5days/weekforperiodsupto65weeks
to 0, 6.25, 20, 62.5, or200 ppm 1,3-butadiene; groups of
90maleand90femalemiceweresimilarlyexposedto625
ppm 1,3-butadiene. The additional animals in the
625-ppm exposure group were included out of concern
that high mortality rates observed previously (5,11) at
this exposure concentration might interfere with the
interim evaluations at weeks 40 and 65. Fifty animals
pergroupwereincludedforevaluationof1,3-butadiene-
induced carcinogenicity after exposure for up to 103
weeks. The 625-ppm concentration corresponds to the
low exposure level in the previous inhalation study
(5,11), while 6.25 ppm and 20 ppm more closely repre-
sent occupational exposure levels to 1,3-butadiene (8).
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Animals were observed twice daily formoribundity and
mortality, and body weights were measured weekly for
the first 13 weeks ofthe study and at 4-week intervals
thereafter.
Studies in which the exposure to 1,3-butadiene was
stopped after limited exposure periods (stop-exposure
studies, SE) were included to assess the relationship
between exposure level and duration ofexposure onthe
outcome of 1,3-butadiene-induced carcinogenicity.
Groups of 50 male mice were exposed to one of the
following regimens: a) 625 ppm for 13 weeks (SE 13
WK), b) 200 ppm for 40 weeks (SE 40 WK), c) 625 ppm
for26weeks(SE 26WK), ord)312ppmfor52weeks(SE
52 WK). After the exposures were terminated, these
groups of animals were placed in control chambers for
theremainderofthe 104-weekstudy. Thetotalexposure
to 1,3-butadiene (concentrationmultipliedbydurationof
exposure, CT) was approximately equivalent for the
firstand secondtreatments (8000and8125ppm-weeks),
anditprovided abouthalfthetotalexposuregiveninthe
third and fourth treatments (16,224 and 16,250 ppm
weeks).
Hematology
Blood samples were obtained atweeks 40and 65 from
the supraorbital sinus of C02-anesthetized mice and
collected into tubes containing EDTA. Red blood cell
count (RBC), whiteblood cellcount(WBC), hemoglobin
concentration (HGB), volume of packed red cells
(VPRC), mean corpuscular volume (MCV), mean cor-
puscular hemoglobin (MCH), mean corpuscular hemo-
globin concentration (MCHC), and platelet counts were
determined with an Ortho ELT-8/ds hematology
analyzer.
Histopathology
Allmoribund animalsandthose sacrificed at40and65
weeks were killed by CO2 asphyxiation and then im-
mediatelynecropsied. Tissuesamples, preservedin 10%
neutral buffered formalin, were embedded in paraffin,
sectioned, and stained with hematoxylin and eosin. The
following tissues were examined microscopically: gross
lesions and tissue masses, bronchial, mediastinal, man-
dibular, and mesenteric lymph nodes; salivary gland;
sternebrae (including marrow); thyroid; parathyroid;
small intestine; large intestine; liver; gall bladder; pros-
tate, testes, epididymis, and seminal vesicles; ovaries;
lungs and mainstem bronchi; nasal cavity and tur-
binates; heart; esophagus; stomach; uterus; brain; thy-
mus; larynx; trachea; pancreas; spleen; kidneys; adre-
nals; urinary bladder; pituitary; and mammary gland.
Statistics
Mean body weights, organ weights, organ weight/
body weight ratios, and hematology results of treated
groups were compared to those ofcontrol groups using
Dunnett's t-test. The minimum level of probability ac-
cepted for significance was p<0.05.
Results
Survival, Body Weight, and Organ Weights
Exposure of B6C3F1 mice to 625 ppm 1,3-butadiene
causedasharpdecreaseinsurvivalofmalesandfemales
(Fig. 1). Increased mortality was apparent in exposed
males at about week 25 and in exposed females at about
week30. Survivalwasreduced50%byweek36formales
andbyweek46forfemales. Allmice exposedto625ppm
1,3-butadiene were dead by week 65. Exposure ofmice
to 200 ppm 1,3-butadiene also caused a reduction in
survival; however, therate ofmortalityatthis exposure
levelwasmuchlessthanthatat625ppm. Atweek65the
survival ofmice exposed to 200 ppm 1,3-butadiene was
43 of50formales and 31 of50 forfemales. Inthe control
and lower exposure concentration groups, survival was
generally greater than 90% at week 65.
Survival data from the stop-exposure groups (Fig. 2)
indicate that although mortality due to exposure to
1,3-butadiene was concentrationrelated, themultiple of
exposure concentrationtimesdurationofexposure (CT)
did not predict the probability of survival. Mortalities
occurred at a greater rate for male mice exposed to 625
ppm 1,3-butadiene for 26 weeks, compared to 312 ppm
for 52 weeks (equivalent total exposure), and for male
mice exposed to 625 ppm for 13 weeks, compared to 200
ppm for 40 weeks.
Exposure of male or female mice to 6.25 to 625 ppm
1,3-butadiene for 65 weeks did not produce any signifi-
cant adverse effects on mean body weight gain. The
initial mean body weight ofmale mice was 22.8 + 0.3 g
and of female mice was 18.5 + 0.2 g. At week 65, the
mean body weight ofcontrol male mice was 49.3 g, and
the mean body weights of the groups of male mice
exposed to 1,3-butadiene ranged from46.0to47.4g; the
meanbodyweightofcontrolfemalemicewas43.5g, and
the mean body weights of the groups of female mice
exposed to 1,3-butadiene ranged from 42.9 to 49.7 g.
At the interim evaluations at weeks 40 and 65, liver,
brain, kidney, spleen, lung, heart, thymus, and testis
weights were measured. The onlysignificant concentra-
tion-related effect was a decrease in testis weight for
males exposed to 62.5 ppm and higher (Table 1). The
testisweight/bodyweightratiowasdecreasedinthe200
and 625 ppm exposure groups, compared to controls. A
similar dose-related decrease in testis weight was ob-
served at the 65-week evaluation.
Hematology
Hematologic indices were measured in blood samples
takenfrommale and female mice atthe 40- and 65-week
interim evaluations. For male mice at week 40, signifi-
cant decreases were observed in red blood cell counts,
hemoglobinconcentration, andpackedredcellvolumeat
exposureconcentrations of62.5, 200, or625ppm 1,3-bu-
tadiene (Table 2). Similar decreases (data not shown)
were observed in female mice exposed to 625 ppm
1,3-butadiene and furtherdemonstrate the dose-related
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FIGURE 1. Survival curves for male and female B6C3F1 mice exposed
to 200 or 625 ppm 1,3-butadiene for 65 weeks.
in male and female mice were not accompanied by in-
creases in reticulocyte counts or in the frequency of
polychromatophilic cells in peripheral blood, and they
mayindicate apartial orpoorlyregenerative responsein
the bone marrow of 1,3-butadiene-exposed mice to re-
Table 1. Testis weights and testis weight/body weight ratios
(x 1000) for male mice exposed to 1,3-butadiene for 40 weeks.
Exposure
concentration, Testis weight, Testis weight/body weight,
ppm mg, ratioa
0 116 ± 6 2.89 ± 0.19
6.25 117 ± 9 2.93 ± 0.28
20 114 9 2.78 0.25
62.5 103 ± 12* 2.87 ± 0.36
200 102 ± 6* 2.54 ± 0.18*
625 60 ± 10* 1.60 + 0.07*
aResults are given as means ± SD; n = 10.
*Different compared to control, p < 0.05.
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FIGURE 2. Survival curves for male B6C3F1 mice exposed to 1,3-
butadiene: stop-exposure groups. Exposure to 1,3-butadiene was
stopped after 13 (SE 13 wk), 26 (SE 26 wk), 40 (SE 40 wk), or 52
weeks (SE 52 wk). After these limited exposure periods, animals
were held in control chambers.
duced levels of circulating erythrocytes. Another
change caused by exposure ofmale and female mice to
1,3-butadiene was an increase in mean corpuscular vol-
ume and in mean corpuscular hemoglobin. A similar
profile ofhematologic changes was observedinmale and
female mice exposed to 625 ppm 1,3-butadiene for 65
weeks.
40-Week Evaluation
Gross and microscopic evaluations ofearly-death mice
at week 40 (i.e., those which died between the start of
the study and week 40), indicated that the predominant
cause ofdeath in the 625-ppm exposure group was lym-
phocyticlymphoma(Table3). Thecumulativenumberof
deaths by week 40 at the lower exposure levels was too
Table 2. Hematologic changes in peripheral blood of male mice exposed to 1,3-butadiene by inhalation for 40 weeks.a
Exposure
concentration, RBC HGB, VPRC, MCV, MCH,
ppm x 106/p.L g/dL mL/dL fL pg
0 10.4 ± 0.3 16.5 ± 0.4 48.1 ± 1.5 46.3 ± 0.8 15.9 ± 0.2
6.25 10.3 ± 0.3 16.4 ± 0.5 47.8 ± 1.7 46.4 ± 1.0 16.0 ± 0.3
20 10.4 ± 0.4 16.7 ± 0.7 48.2 ± 2.2 46.3 ± 0.8 16.1 ± 0.4
62.5 9.9 ± 0.4* 15.9 ± 0.6* 45.9 ± 2.1* 46.7 ± 1.2 16.1 ± 0.3
200 9.6 ± 0.5* 15.6 ± 0.9* 45.4 + 2.7* 47.2 ± 1.0 16.2 ± 0.2*
625 7.6 ± 1.2* 13.5 ± 1.8* 39.9 5.3* 53.2 ± 2.9* 17.9 ± 0.8*
a n= 10.
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Table 3. Incidence of microscopic lesions in early death mice
(through week-40) exposed to 625 ppm 1,3-butadiene.
SE SE
Malesa Femalesa week 13b week 26
Target: lesion n = 49 n = 21 n = 10 n = 20
Lymphocytic lymphoma 43 16 9 19
Heart:
Endothelial hyperplasia 2 0 0 0
Forestomach:
Epithelial hyperplasia 22 11 3 9
Squamous cell neoplasm 1 2 0 1
Lung:
Alveolar epithelial hyperplasia 3 1 0 0
Alveolar-bronchiolar neoplasm 1 2 0 1
Gonad:
Atrophy 35 15 2 4
aNumberofearlydeathanimals:males, n = 49;females, n = 21. There were
no deaths in either the male or female control groups.
bSE, stop-exposure groups (males).
few(3/group orless)todemonstrateanypotentialtrend.
However, these deaths were generally due to lympho-
cytic lymphoma and included three mice at 200 ppm and
onemouseat62.5ppm. Malemiceweremoresusceptible
to 1,3-butadiene-induced lymphoma than females; by
week 40, lymphocytic lymphoma was observed in 43 of
49 early-death males and 16 of 21 early-death females
exposed to 625 ppm 1,3-butadiene.
Lymphocytic lymphomas occurred in most early-
death mice in the stop-exposure (SE) groups (Table 3).
Ten of 50 male mice exposed to 625 ppm 1,3-butadiene
for 13 weeks and 20 of50 male mice exposed to 625 ppm
1,3-butadiene for 26 weeks died by week 40. Twenty-
eight of these deaths were due to lymphocytic lym-
phoma. The mortality rate and the incidence oflympho-
cytic lymphoma was markedly reduced in those groups
exposed to lower concentrations of 1,3-butadiene for a
longer duration (comparable total exposures); lympho-
cytic lymphoma was present in only two male mice
exposed to 200 ppm 1,3-butadiene for 40 weeks and one
male mouse exposed to 312 ppm.
The incidence of other tumor types, typically later
appearingthan lymphocytic lymphoma, were too few to
clearlydemonstrate anexposure-related effect. The low
incidences of squamous cell neoplasms of the fore-
stomach and alveolar-bronchiolar neoplasms observed
by week 40 are noteworthy since they are uncommon,
especially in 46 to 47-week-old B63CF1, and because
they had been observed at increased incidences in the
previous inhalation study in mice (5,11). Epithelial hy-
perplasiaoftheforestomachwasobservedinover50%of
themicedyingbyweek40thatwereexposedto625ppm
1,3-butadiene. Testicular and ovarian atrophy, lesions
observed athighrates intheprevious study(5,11), were
prominent in this study as well.
The incidence of selected histopathologic lesions in
groups of10male or 10femalemicekilled atweek40 are
shown in Table 4. Lymphocytic lymphomas were ob-
served in two males and one female exposed to 625 ppm
1,3-butadiene. The low incidence of lymphocytic lym-
phoma in these animals, compared to the early-death
mice (Table 3), reflects the rapid onset of a moribund
condition in lymphoma-bearing mice. Proliferative le-
sions of the forestomach (epithelial hyperplasia and
squamouscellpapilloma)werepresentinbothmalesand
females exposed to 625 ppm 1,3-butadiene. Epithelial
hyperplasia of the forestomach was observed in one
female mouse exposed to 200 ppm 1,3-butadiene. The
incidences of alveolar epithelial hyperplasia and alve-
olar-bronchiolar neoplasms were increased in male and
female mice exposed to 625 and 200 ppm 1,3-butadiene,
butnotto62.5ppm1,3-butadiene. Testicularatrophy, of
minimal to mild severity, was present in 6 of 10 males
exposed to625ppm 1,3-butadiene. Ovarianatrophywas
markedinfemalemice exposedto200or625ppm 1,3-bu-
tadiene, while ovaries of mice exposed to 62.5 ppm
appeared normal. The atrophic ovaries had no identifia-
ble oocytes, follicles, or corpora lutea. A granulosa cell
neoplasmoftheovarywasobservedinonefemalemouse
in the 200-ppm dose group. Hemangiosarcomas of the
heart were not observed in animals sacrificed at the
40-week interim evaluation; however, endothelial hy-
perplasia, a proliferative vascular lesion of the heart,
was observed in one maleand one female exposed to 625
ppm 1,3-butadiene for 40 weeks and two early death
male mice exposed to 625 ppm 1,3-butadiene.
65-Week Evaluation
Data from the 65-week interim sacrifice ofmale mice
(Table 5) show that exposure to 1,3-butadiene resulted
in dose-related increases in the incidences of prolifera-
tivelesions oftheheart, forestomach, lung, and Harder-
ian gland (a site not identified in the previous study).
Only 7ofthe 90male miceexposedto 625ppmbutadiene
survived until week 65. Proliferative responses were
induced in male mice at concentrations as low as 62.5 or
20 ppm after 65 weeks of exposure. Testicular atrophy
was observed only in the 625-ppm exposure group.
Theinterim sacrifice offemale mice atweek 65 (Table
6) also revealed 1,3-butadiene-induced proliferative
Table 4. Incidence of microscopic lesions in mice exposed to
1,3-butadiene for 40 weeks.a
Exposure concentration, ppm
Males Females
Target: lesion 0 200 625 0 200 625
Lymphocytic lymphoma 0 0 2 0 0 1
Forestomach:
Epithelial hyperplasia 0 0 6 0 1 6
Squamous cell papilloma 0 0 3 0 0 2
Lung.
Alveolar epithelial hyperplasia 0 3 3 0 0 1
Alveolar-bronchiolar neoplasm 1 2 4 0 3 1
Gonad:
Atrophy 0 0 6 0 9 8
an = 10, exceptforfemalemiceexposedto625ppm1,3-butadienewheren = 8.
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Table 5. Incidence of microscopic lesions in male mice exposed
to 1,3-butadiene for 65 weeks.a
Exposure concentration, ppm
Target: lesion 0 6.25 20 62.5 200 625
Lymphocytic lymphoma 0 0 0 0 0 2
Heart:
Endothelial hyperplasia 0 NEb 0 1 1 1
Hemangiosarcoma 0 NE 0 0 1 3
Forestomach:
Epithelial hyperplasia 0 0 0 1 0 2
Squamous cell neoplasm 0 0 0 1 3 4
Lung:
Alveolar epithelial hyperplasia 0 0 1 1 3 2
Alveolar-bronchiolar neoplasm 0 0 0 2 4 5
Harderian gland:
Adenoma 0 0 2 4 3 3
Liver:
Hepatocellular neoplasm 3 1 5 3 4 6
Testis:
Atrophy 0 NE NE NE 0 4
an = 10, except for mice exposed to 625 ppm 1,3-butadiene where
n = 7.
bNE, not examined microscopically.
Table 6. Incidence of microscopic lesions in female mice
exposed to 1,3-butadiene for 65 weeks.a
Exposure concentration, ppm
Target: lesion 0 6.25 20 62.5 200 625
Lymphocytic lymphoma 1 0 0 0 3 0
Heart:
Endothelial hyperplasia 0 NEb NE 0 4 0
Hemangiosarcoma 0 NE NE 0 1 2
Forestomach:
Epithelial hyperplasia 0 0 0 0 2 1
Squamous cell neoplasm 0 0 0 1 2 1
Lung:
Alveolar epithelial hyperplasia 0 0 2 1 4 0
Alveolar-bronchiolar neoplasm 0 0 0 3 4 2
Liver:
Hepatocellular neoplasm 1 1 1 1 3 1
Ovary:
Atrophy 0 0 2 9 8 2
an = 10, except for mice exposed to 625 ppm
n = 2.
bNE, not examined microscopically.
1,3-butadiene where
changes in the heart, forestomach, and lung, especially
at200and 62.5 ppm 1,3-butadiene. Onlytwofemalemice
exposed to 625 ppm 1,3-butadiene survived until week
65. Ovarian atrophy was observed at exposure levels of
20 ppm and higher.
The cumulative incidence of microscopic lesions in
early-death mice through week 65 shows that lympho-
cytic lymphoma was the major cause ofdeath at the 625
ppm exposure level, especially for male mice (Table 7).
Between week40 and week 65, 24 male mice exposed to
625 ppm 1,3-butadiene died; 18 had lymphocytic lym-
phoma. Increased incidences of hemangiosarcomas of
the heart, forestomach neoplasms, alveolar-bronchiolar
neoplasms, Harderianglandadenomas, andhepatocellu-
larneoplasms werealsoevidentinearly-deathmalemice
exposed to 625 ppm 1,3-butadiene. The number ofearly
deaths in male mice exposed to 62.5 or 200 ppm 1,3-
Table 7. Incidence of microscopic lesions in early-death mice
(through week 65) exposed to 1,3-butadiene.
Exposure concentration, ppm
Males Females
62.5 200 625 62.5 200 625
Target: lesion (4)a (7) (73) (6) (19) (80)
Lymphocytic lymphoma 1 2 61 1 6 36
Heart:
Endothelial hyperplasia 0 0 6 1 4 9
Hemangiosarcoma 0 0 3 0 3 24
Forestomach:
Epithelial hyperplasia 0 1 39 3 5 41
Squamous cell neoplasm 0 0 6 0 0 26
Lung:
Alveolar epithelial hyperplasia 0 0 9 1 4 10
Avelolar-bronchiolar neoplasm 1 3 3 1 5 22
Harderian gland:
Adenoma 0 1 4 0 5 6
Mammary gland:
Adenocarcinoma 1 3 11
Ovary:
Granulosa cell neoplasm 0 2 5
Liver:
Hepatocellular neoplasm 1 1 5 0 4 2
Gonad:
Atrophy 0 1 53 4 15 68
aNumbers in parentheses equal the number ofearly death animals
in each group. Only one control male mouse and one control female
mouse died during the first 65 weeks of the study; hepatocellular
adenoma was observed in the male mouse.
butadiene was too low to ascertain any potential carcin-
ogeniceffects. Fifty-ninefemalemicethatwereexposed
to 625 ppm died between week 40 and week 65; 20 had
lymphocytic lymphoma. The incidence ofotherprimary
tumors washighinthese 59 mice: 24hemangiosarcomas
of the heart, 24 squamous cell neoplasms of the fore-
stomach, 20 alveolar-bronchiolar neoplasms, 6 Harder-
ian gland adenomas, 11 mammary gland adenocarci-
nomas, and 5 granulosa cell neoplasms of the ovary.
Elevated incidences of neoplasms at these sites were
also apparent in early-death female mice exposed to 200
ppm 1,3-butadiene. The development of neoplasms in
the heart, forestomach, and lung were supported by
high incidences ofhyperplasias in these organs in both
malesandfemales. Testicularatrophywasobservedata
high incidence in male mice exposed to 625 ppm, while
ovarianatrophywasobservedinfemalemiceexposedto
62.5, 200, or 625 ppm 1,3-butadiene.
The tumor incidence profiles in the stop-exposure
groups (Table 8) indicate that at comparable total expo-
sures, the occurrence oflymphocytic lymphomais more
likely with exposure to a higher concentration of 1,3-
butadiene for a short time, compared to exposure to a
lower concentration for an extended duration. This is
evident by comparingthe incidence oflymphocytic lym-
phoma in the 625 ppm SE 13WKgroup (15 lymphocytic
lymphomas)withthatinthe200ppmSE40WKgroup(3
lymphocytic lymphomas), and comparing the incidence
inthe625ppmSE 26WKgroup(30lymphocyticlympho-
mas) with that in the 312 ppm SE 52 WK group (3
lymphocytic lymphomas). An obscuring effect of a high
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incidence of lymphocytic lymphoma on 1,3-butadiene-
induced neoplasia at other primary sites is evident by
comparing the tumor profile in the 312 ppm SE 52 WK
group with that in the 625 ppm SE 26 WK group. The
incidences ofhemangiosarcomas ofthe heart, alveolar-
bronchiolar neoplasms, and hepatocellular neoplasms
were higher in the group with the lower incidence of
lymphocyticlymphoma (312 ppm SE 52WK), indicating
that longer survival allows these other chemically in-
duced tumors to manifest. Graphic presentation ofthe
incidences oflymphocytic lymphomas and hemangiosar-
comas ofthe heart versus weeks on study forthese two
stop-exposure groups (Fig. 3) shows that hemangiosar-
comas ofthe heart are more likely to be observed when
the incidence of early lymphocytic lymphomas is low;
conversely, when the rate of early lymphocytic lym-
phoma is high, the incidence of 1,3-butadiene-induced
hemangiosarcoma ofthe heart is low.
Discussion
1,3-Butadiene has been shown to induce multiple or-
gan carcinogenicity in rats and mice (5,11,14). In
B6C3F1 mice, exposure to 625 or 1250 ppm 1,3-
butadiene caused early induction and significantly in-
creased incidences of malignant lymphomas, hem-
angiosarcomas of the heart, alveolar-bronchiolar neo-
plasms, squamous cell neoplasms of the forestomach,
acinarcell carcinomas ofthe mammarygland, granulosa
cell neoplasms of the ovary, and hepatocellular neo-
plasms (5,11); Sprague-Dawley rats exposed to 1000 or
8000 ppm 1,3-butadiene had increased incidences at
multiple sites: pancreatic exocrine adenomas, uterine
sarcomas, Zymbal gland carcinomas, mammary gland
neoplasms, thyroidfollicularcellneoplasms, and Leydig
cell neoplasms ofthe testis (14). Morphological descrip-
Table 8. Incidence ofmicroscopic lesions in early-death male
mice: stop-exposure (SE) groups through week 65.
Exposure concentration, ppma
200 625 312 625
SE 40 SE 13 SE 52 SE 26
Target: lesion (8000)a (8125) (16224) (16250)
Lymphocytic lymphoma 3 15 3 30
Heart:
Endothelial hyperplasia 0 1 1 5
Hemangiosarcoma 1 0 12 4
Forestomach:
Epithelialhyperplasia 2 5 12 13
Squamous cell neoplasm 0 3 3 9
Lung:
Alveolareipthelialhyperplasia 1 0 3 4
Alveolar-bronchiolarneoplasm 13 9 5
Harderian gland:
Adenoma 1 1 3 2
Liver:
Hepatocellular neoplasm 2 0 8 4
Testis:
Atrophy 0 2 1 5
aNumberofearly-deathaninalsineachgroup(n):200ppm, SE40, n = 7;625
ppm, SE 13, n = 20; 312 ppm, SE 52, n = 21; 625 ppm, SE 26, n = 36.
nTotal exposure expressed as ppm-weeks.
tions and illustrations of the neoplastic lesions induced
by 1,3-butadiene in B6C3F1 mice are presented in the
followingpaper(15). Thelargenumberofprimaryorgan
sites of tumor induction by 1,3-butadiene was unusual
forchemicals studied bythe NTP; only 1.9% ofapproxi-
mately360 chemicals evaluated showed evidence ofcar-
cinogenicity at six or more primary sites.
Although the previous mouse study was ended after
only 60 weeks ofexposure because ofhighrates ofearly
mortality (5,11), the doses used in that study are not
considered excessive for evaluation of carcinogenicity,
since survival was not reduced from toxic effects other
than from the induction of fetal neoplasms. Further-
more, those concentrations (625 and 1250 ppm) are
equivalenttoandbelowthe OSHAstandardof1000ppm
for occupational exposure to 1,3-butadiene (16). An-
nouncements have beenmade to lowerthislevelconsid-
erably (17).
The results ofthe studies of1,3-butadiene in mice are
unusualinthatuncommontumors, suchashemangiosar-
coma of the heart and squamous cell neoplasms of the
forestomach, wereinduced afterinhalationexposure. In
untreated B6C3F1 mice 110 to 112 weeks of age, the
historical rate for hemangiosarcomas of the heart is
about 0.04% (1 in 2500), while that of squamous cell
neoplasms of the forestomach is about 0.5% (1 in 200)
(12). In the present studies, Harderian gland adenomas
were observed in early-death mice (through week 65)
exposed to 200 or 625 ppm 1,3-butadiene and at the
65-weekinterimevaluation. Theseobservationsindicate
an additional site of tumor induction by 1,3-butadiene;
_ o Lymphoma, 625ppmSE 26wk
* Lymphoma, 312 ppm SE52wk
I o Hemongiosorcoma, 625 ppm SE 26wk 60
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FIGURE 3. Cumulative incidenceoflymphocyticlymphomas orheman-
giosarcomas of the heart versus weeks on study in two stop-
exposure groups for which the total exposures to 1,3-butadiene
were comparable (625 ppm SE 26 wk and 312 ppm SE 52 wk).
33MELNICK ET AL.
the historical rate ofHarderian gland neoplasms in un-
treated 110- to 112-week-old B6C3F1 mice is approxi-
mately 2% (12).
The present inhalation studies of 1,3-butadiene were
performed to better characterize dose-response rela-
tionships for butadiene-induced neoplastic and nonneo-
plastic lesions in B6C3F1 mice at various intervals and
after 2 years ofexposure. The following conclusions are
based onthe results ofthe40-weekand 65-weekevalua-
tions. 1,3-Butadiene is a gonadal toxicant in mice, in-
ducing testicular atrophy in males at 625 ppm, and
ovarian atrophy in females at 20 ppm and higher. This
gas was alsotoxic tothebone marrowofmice, causinga
partially orpoorlyregenerative dose-dependent anemia
at exposure concentrations of62.5 ppm and higher. The
increase in MCV and MCH at 625 ppm 1,3-butadiene
indicates that although 1,3-butadiene caused suppres-
sion ofhematopoiesis in the bone marrow, younglarger
cells may have been released into the blood from extra-
medullary sites. It has been reported that exposure of
B6C3F1 mice to 1250 ppm 1,3-butadiene produces a
macrocytic-megaloblastic anemia (18) and promotes ex-
tramedullary hematopoiesis in the spleen (19).
For male or female mice exposed to 625 ppm 1,3-
butadiene, lymphocytic lymphoma was the major cause
ofdeath inthe first 50weeks ofthe study. Priortoweek
65, the lowest exposure concentration at which lympho-
cytic lymphomas were observed was 62.5 ppm; lympho-
cytic lymphoma was observed in one male mouse ex-
posed to this concentration of 1,3-butadiene for 29
weeks. Lymphocytic lymphomas were also induced in
male mice exposed to 625 ppm 1,3-butadiene for only 13
weeks (i.e., stop-exposure study). Theincidence oflym-
phocytic lymphoma was two times higher in male mice
exposed to 625 ppm 1,3-butadiene for 26 weeks, com-
pared to male mice exposed to 625 ppm for 13 weeks.
When the exposure concentration was reduced to 312
ppm and the exposure duration was extended to 52
weeks (312 ppm SE 52 WK), the incidence of lympho-
cyticlymphoma was 10% ofthe incidence inthe group of
mice that received the same total exposure to 1,3-
butadiene (625 ppm SE 26 WK). Thus, the multiple of
exposure concentration times exposure duration does
not predict the incidence of lymphocytic lymphoma in
mice. At equivalent total exposures, the likelihood for
induction oflymphocytic lymphoma is greater with ex-
posure to a higher concentration of 1.3-butadiene for a
shorter time than for exposure to a lower concentration
of 1,3-butadiene over an extended duration.
The early mortalities due to lymphocytic lymphomas,
especially in male mice exposed to 625 ppm 1,3-
butadiene, appear to limit the expression ofneoplasms
at other sites. Increased incidences of hemangiosar-
comas of the heart, squamous cell neoplasms of the
forestomach, alveolar-bronchiolar neoplasms, Harder-
ian gland adenomas, adenocarcinomas ofthe mammary
gland, granulosa cell neoplasms ofthe ovary, and hepa-
tocellular neoplasms were frequently observed in
1,3-butadiene-exposed micethatdiedbetweenweeks45
and 65ofthe study. Since earlylymphocyticlymphomas
were not as prevalent at concentrations of 6.25 to 200
ppm, it is likely that a clearer dose response for
1,3-butadiene-induced neoplasia at these sites will be
obtained over this concentration range. The lack of a
clear dose response for some ofthe neoplastic and non-
neoplastic lesions observed in the previous inhalation
study of1,3-butadiene in B6C3F1 mice (5,11) was likely
due to reduced survival caused by early development of
malignant lymphomas. Proliferative, nonneoplastic le-
sions of the forestomach, heart, and lung which were
observed in early-death mice and at the 40-week and
65-week evaluations may represent treatment related
preneoplastic changes at these target sites.
The carcinogenicity studies of 1,3-butadiene in rats
and in mice demonstrate a species difference with re-
spect to sites of tumor induction and magnitude of re-
sponse. Ironsandcoworkers(20,21)havesuggestedthat
activation of an endogenous ecotropic retrovirus may
play a critical role in butadiene-induced thymic
lymphomalleukemiainB6C3F1mice. However, thefind-
ing that exposure to 1250 ppm 1,3-butadiene for up to 1
year also caused a 14% incidence ofthymic lymphoma/
leukemia in NIH Swiss mice, a strain that does not
express the endogenous ecotropic retrovirus recovered
fromtissues ofB6C3F1 mice. Further, Swissmicehave
a background rate of zero for this neoplasm, indicating
that 1,3-butadiene can induce thymic lymphoma inde-
pendently ofthis activated retrovirus.
Butadiene monoxide (1,2-epoxybutene-3) has been
identified as the primary metabolite of 1,3-butadiene
biotransformation by rat liver microsomal monooxy-
genase (22). This intermediate may be further metab-
olized by liver monooxygenase or epoxide hydrolase to
diepoxybutane or 3,4-epoxy-1,2-butanediol, respec-
tively (23). Butadiene monoxide and diepoxybutane
have been shown to be mutagenic to Salmonella ty-
phimurium strains, which are sensitive to base pair
substitution mutagens (24,25), and to induce local neo-
plasmswhenappliedtotheskinofmiceorwhenadminis-
tered to rats or mice by subcutaneous injection (26,27).
Since 1,3-butadiene is mutagenic to Salmonella ty-
phimurium only when incubated with liver S-9 activa-
tion systems (28), epoxide intermediates may be the
ultimate carcinogenic forms ofthis chemical. Butadiene
monoxide has been identified in the expired air of
Sprague-Dawley rats exposed to 1,3-butadiene (29).
Although the rate ofbutadiene metabolism is greaterin
B6C3F1 mice than Sprague-Dawley rats at equivalent
exposure concentrations (30-32), the magnitude ofthis
difference at carcinogenic exposure levels in these spe-
cies does not seem to be sufficient to account for the
species difference in carcinogenicity of 1,3-butadiene.
The present studies indicate that 200 ppm butadiene is
carcinogenic to the heart, lung, Harderian gland, mam-
mary gland, and ovary ofB6C3F1 mice; however, other
than for the mammary gland, neoplasms were not in-
duced at these sites in Sprague-Dawley rats exposed to
1000 or 8000 ppm 1,3-butadiene. The metabolism of
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1,3-butadiene is greater in Sprague-Dawley rats ex-
posed to 1000 ppm 1,3-butadiene than in B6C3F1 mice
exposed to 200 ppm 1,3-butadiene (30,31). Perhaps
steady-state tissue concentrations of these intermedi-
ates at target sites are sufficiently different to account
for the species difference in carcinogenicity of1,3-buta-
diene.
The inhalation carcinogenicity studies of 1,3-buta-
diene in rats and mice have raised concerns of risk for
humans exposed to this chemical. Results of epidemi-
ology studies indicate an association between occu-
pational exposure to 1,3-butadiene andthe development
of lymphatic and hematopoietic neoplasms (33-36).
These findings are consistent with the results of the
inhalation studies of 1,3-butadiene in mice.
NOTE ADDED IN PROOF: Data from the 2-year ex-
posure studies clearly showed that the incidence of
alveolar-bronchiolar neoplasms in female B6C3F1, mice
wasincreasedatallexposureconcentrationsofof1,3-bu-
tadiene, including 6.25ppm, compared to controls (R.L.
Melnick et al., Cancer Res., in press).
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